Y-mAbs to Announce 2021 Financial and Operating Results on February 24, 2022
February 17, 2022 09:00 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the year ended December...
Y-mAbs Announces Completion of Pre-BLA Meeting with FDA for Omburtamab
February 11, 2022 09:00 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference
January 05, 2022 09:00 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and...
UPDATE - Y-mAbs Announces Pipeline Update
December 15, 2021 09:53 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs Announces Pipeline Update
December 15, 2021 09:00 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs Hosting Virtual Research and Development Day
December 06, 2021 16:05 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs Announces Third Quarter Financial Results and Recent Corporate Developments
November 04, 2021 16:05 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs Provides Regulatory Update on Omburtamab for the Treatment of Patients with Neuroblastoma CNS/LM Metastasis
November 04, 2021 09:00 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs to Announce Third 2021 Financial and Operating Results on November 4, 2021
October 28, 2021 16:01 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the quarter ended...
Y-mAbs’ 177Lu-omburtamab-DTPA for the Treatment of Patients with Medulloblastoma Granted Rare Pediatric Disease Designation by FDA
October 07, 2021 09:00 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (“Y-mAbs” or the “Company”) (NASDAQ: YMAB), a commercial-stage biopharmaceutical company focused on the development and...